Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Jesionek-Kupnicka D, Szybka M, Malachowska B, Fendler W, Potemski P, Piaskowski S, Jaskolski D, Papierz W, Skowronski W, Och W, Kordek R, Zawlik I.

DNA Cell Biol. 2014 Apr;33(4):217-26. doi: 10.1089/dna.2013.2201.


O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.

Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.

Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Review.


High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.

Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik I, Szybka M, Kulczycka-Wojdala D, Rieske P, Sieruta M, Jaskolski D, Och W, Skowronski W, Sikorska B, Potemski P, Papierz W, Liberski PP, Kordek R.

Cancer Genet Cytogenet. 2009 Jan 15;188(2):77-82. doi: 10.1016/j.cancergencyto.2008.09.015.


TP53 promoter methylation in human gliomas.

Amatya VJ, Naumann U, Weller M, Ohgaki H.

Acta Neuropathol. 2005 Aug;110(2):178-84.


Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.

Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP.

Asian Pac J Cancer Prev. 2014;15(24):10893-8.


Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.

Su Y, Yin L, Liu R, Sheng J, Yang M, Wang Y, Pan E, Guo W, Pu Y, Zhang J, Liang G.

Med Oncol. 2014 Feb;31(2):784. doi: 10.1007/s12032-013-0784-4.


Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network..

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017.


Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.

Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki K.

Ann Surg Oncol. 2005 May;12(5):354-63.


O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.

Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T.

Int J Cancer. 2005 Feb 10;113(4):581-7.


Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.

Laskar RS, Ghosh SK, Talukdar FR.

Mol Carcinog. 2015 Dec;54(12):1786-95. doi: 10.1002/mc.22250.


Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.

Lee SM, Choi JE, Na YK, Lee EJ, Lee WK, Choi YY, Yoon GS, Jeon HS, Kim DS, Park JY.

Lung Cancer. 2013 Aug;81(2):194-9. doi: 10.1016/j.lungcan.2013.04.013.


Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.

Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK.

Clinics (Sao Paulo). 2011;66(10):1747-55.


MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN.

J Neurooncol. 2011 Feb;101(3):405-17. doi: 10.1007/s11060-010-0274-x.


A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.

Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, Sharma MC, Sharma BS, Mahapatra AK, Suri A, Sarkar C.

J Clin Neurosci. 2011 Jan;18(1):66-70. doi: 10.1016/j.jocn.2010.04.050.


Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.

Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM, Lu FM.

World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317. Review.


Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.

Wang P, Rao J, Yang H, Zhao H, Yang L.

J Surg Oncol. 2011 Nov 1;104(6):679-84. doi: 10.1002/jso.22004.


p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.

Novello C, Pazzaglia L, Conti A, Quattrini I, Pollino S, Perego P, Picci P, Benassi MS.

PLoS One. 2014 Dec 9;9(12):e114757. doi: 10.1371/journal.pone.0114757.


Defective p53 antiangiogenic signaling in glioblastoma.

Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M.

Neuro Oncol. 2010 Sep;12(9):894-907. doi: 10.1093/neuonc/noq051.


Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, Lv Q, Zheng H, Zhong XY.

Hum Mol Genet. 2010 Aug 1;19(15):2936-46. doi: 10.1093/hmg/ddq199.


The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.

Finkova A, Vazna A, Hrachovina O, Bendova S, Prochazkova K, Sedlacek Z.

Cancer Genet Cytogenet. 2009 Aug;193(1):63-6. doi: 10.1016/j.cancergencyto.2009.04.014.

Items per page

Supplemental Content

Support Center